Ajanta Pharma Ltd

Pharmaceuticals - Indian - Formulations

NSE: AJANTPHARM Mid Cap ISIN: INE031B01049
As on 06 November 2024 at 11:14
As on 06 November 2024 at 11:14
3,085.75
-25.95
(-0.83%)
Over 1 Month
-5.99%
Over 6 Months
28.87%
Over 1 Year
71.22%
Over 3 Years
113.65%
Summary
Close 3,085.75
Open 3,124.95
High 3,125
Low 3,083.95
Volume 27,022
Net Turnover 62,64,79,694.20
52 Week High 3,485
52 Week Low 1,783.50
52Wk High / Low
1,783.50
3,485
Key Financial Data
Market Cap (in ₹ Cr) 38,868.90
EPS 68.36
Book Value (BV) 282.56
Div. Yield 1.66
P/E 45.50
Price/Book Value 11.01
Delivery % 37.77
Face Value 2
Key Ratios
P/E ratio 35.03
P/B ratio 8.28
EV to Sales 7.09
PEG Ratio 0.79
ROA 23.15
ROE 24.24
Debt-Equity 0.01
Net Profit Margin 20.33
Operating Profit Margin 31.12

Peer Comparison

Company LTP Market Cap (in ₹ Cr)
Ajanta Pharma Ltd ₹3,110.40 ₹38,852.66
Sun Pharmaceuticals Industries Ltd ₹1,803.25 ₹4,32,660.08
Divis Laboratories Ltd ₹5,808.20 ₹1,54,189.46
Cipla Ltd ₹1,601.25 ₹1,29,316.22
Mankind Pharma Ltd ₹2,714.40 ₹1,08,750.85
Torrent Pharmaceuticals Ltd ₹3,186.35 ₹1,07,835.72

News

Ajanta Pharma Ltd spurts 2.75%, rises for third straight session

Ajanta Pharma Ltd is quoting at Rs 3079.05, up 2.75% on the day as on 12:49 IST on the NSE. The stock is up 68.48% in last one year as compared to a 27.41% gain in NIFTY and a 54.09% gain in the Nifty Pharma index.

31 Oct 2024

Ajanta Pharma gains after Q2 PAT jumps 11% YoY to Rs 216 cr; declares dividend of Rs 28/ share

Ajanta Pharma rose 1.13% to Rs 2,954 after the company's consolidated net profit jumped climbed 10.84% to Rs 216.48 crore on 15.38% increase in revenue from operations to Rs 1,186.64 crore in Q2 FY25 over Q2 FY24.

29 Oct 2024

Board of Ajanta Pharma recommends First Interim Dividend

Of Rs.28 per share

28 Oct 2024

Ajanta Pharma Ltd eases for fifth straight session

Ajanta Pharma Ltd is quoting at Rs 2974.35, down 0.1% on the day as on 13:19 IST on the NSE. The stock jumped 32.98% in last one year as compared to a 28.37% rally in NIFTY and a 53.74% spurt in the Nifty Pharma index.

23 Oct 2024

Ajanta Pharma to hold board meeting

On 28 October 2024

17 Oct 2024

Financials

Profit and Loss

Particulars (in ₹ Cr.) FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Total Revenue 4,087.60 3,544.02 3,280.37 2,822.16 2,380.62
Total Expenses 2,990.65 2,844.17 2,379.83 1,920.07 1,764.03
Profit Before Tax 1,096.95 699.85 900.54 902.09 612.67
Profit After Tax 807.24 558.72 719.86 675.64 441.13
Operating Profit after Depreciation 1,103.75 705.08 909.66 908.99 625.69

Balance Sheet

Particulars (in ₹ Cr.) FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Fixed Assets 1,464.89 1,484.01 1,483.91 1,509.89 1,439.93
Total Non Current Assets 1,775.77 1,753.60 1,723.48 1,695.85 1,634.07
Total Current Assets 2,441.67 2,551.19 2,057.01 1,836.21 1,415.08
TOTAL ASSETS 4,217.44 4,304.79 3,780.49 3,532.06 3,049.15
Total Shareholder's Fund 3,413.57 3,246.45 3,169.18 2,884.98 2,461.30

Cash Flow

Particulars (in ₹ Cr.) FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Net Cash from Operating Activities 735.35 736.29 542.34 466.99 300.88
Net Cash used in Investing Activities 105.02 -501.31 -66.04 -162.68 -115.91
Net Cash used in Financing Activities -1,047.70 -105.12 -457.30 -268.90 -134

Corporate Actions

Ajanta Pharma Ltd

₹28/Share

Announcement Date 06 Nov 2024
Record Date 06 Nov 2024
Div Yield 1400%

About Ajanta Pharma Ltd

Ajanta Pharmaceuticals Ltd. was established in the year 1973. Headquartered in Mumbai, India, the company has grown into a prominent player in the pharmaceutical industry. It specialises in developing, manufacturing, and marketing pharmaceutical formulations across various therapeutic segments. This includes cardiology, dermatology, ophthalmology, and pain management.

Mr. Yogesh Agrawal (Managing Director) owns 14.47% of the company’s equity. Rajesh M Agrawal (Joint Managing Director) also owns a 14.47% stake in the company. Under the leadership of the Agrawal family, Ajanta Pharma has established a strong reputation for producing high-quality medicines. The company has expanded its reach to over 30 countries across Africa, South East Asia, West Asia, and the CIS region. Apart from the Agrawal family, some managerial promoters have contributed to the company’s success. They are
  • K H Viswanathan
  • Anjana Grewal
  • Prabhakar R Dalal
  • Chandrakant M Khetan

Ajanta Pharma’s product portfolio encompasses a range of generic medicines and branded formulations, with popular offerings in cardiovascular health, skincare, eye care, and pain relief. The company is recognized for its innovative approach. This has helped it secure leadership positions in multiple molecules and therapeutic areas.

It is not explicitly labelled as the top stock in its sector. However, Ajanta Pharma’s significant market presence and growth trajectory reflect its importance in the pharmaceutical industry. The company’s registered office is located in Kandivali (West), Mumbai. Meanwhile, its registrars are based at L.B.S. Marg, Vikhroli.

Ajanta Pharma’s focus on quality and strategic expansion has positioned it as a key player in the pharmaceutical sector. As the company continues to grow and penetrate new markets, it remains dedicated to its mission of providing high-quality, affordable medicines to patients worldwide.

How Ajanta Pharma Leads in New Product Development

Ajanta Pharma’s leadership in new product development is a result of its strategic focus on innovation, quality, and market needs. Established in 1973, the company has grown to become a significant player in the pharmaceutical industry. It is known for its ability to introduce new and effective medications across various therapeutic segments.

Ajanta Pharma places a strong emphasis on research and development (R&D). The company invests significantly in its R&D facilities, which are equipped with the latest technology. These facilities are staffed by a team of highly skilled scientists and researchers. This commitment to R&D enables Ajanta Pharma to stay ahead of the curve in developing new formulations and improving existing ones. The company’s R&D efforts are focused on creating value-added products that meet the needs of patients and healthcare providers.

One of the key factors behind Ajanta Pharma’s success in new product development is its deep understanding of market needs. The company conducts extensive market research to identify gaps in areas where new treatments are needed. This approach ensures that the products developed by Ajanta Pharma are relevant to real-world health issues.

Quality is at the core of Ajanta Pharma’s product development process. The company adheres to stringent quality control measures at every stage of production, from raw material sourcing to final product packaging. This focus on quality ensures that the products are safe, effective, and meet international standards. Ajanta Pharma’s commitment to quality has earned it a strong reputation in the pharmaceutical industry.

Ajanta Pharma has also leveraged strategic partnerships and collaborations. This is to enhance its product development capabilities. The company has partnered with leading research institutions and other pharmaceutical companies. This allows it to access new technologies and expertise that complement its own capabilities. As a result, these collaborations have enabled Ajanta Pharma to accelerate the development of new products.

Ajanta Pharma’s diverse product portfolio is another testament to its leadership in new product development. It offers diverse products across various therapeutic segments, including cardiology and pain management. This diversity allows the company to cater to a broad spectrum of healthcare needs. It also allows Ajanta Pharma to reduce its dependence on any single product or market.

Navigating the complex regulatory landscape is a critical aspect of new product development in the pharmaceutical industry. Ajanta Pharma has a dedicated regulatory affairs team. They ensure all products comply with the regulatory requirements of different markets. This approach to regulatory compliance helps the company avoid delays in product launches. It also ensures that its products are approved for use in multiple countries.

Ajanta Pharma’s customer-centric approach is integral to its new product development strategy. The company seeks feedback from healthcare professionals and patients to understand their preferences. This feedback is then incorporated into the product development process to create user-friendly and effective solutions. Ajanta Pharma ensures that its products are well-received in the market by prioritising the needs of its customers.

Ajanta Pharma’s leadership in new product development is a result of its strategic focus on innovation, quality, and market needs. As Ajanta Pharma continues to grow and expand its reach, it remains dedicated to developing new and effective medications that improve the health and well-being of patients around the world.

FAQ’s

What is the share price of Ajanta Pharma Ltd today?
Ajanta Pharma Ltd share price as on 6 Nov 2024 is ₹3085.75
What is the Market Cap of Ajanta Pharma Ltd?
The market cap of Ajanta Pharma Ltd stock is ₹38,868.90 Cr.
What is the PE Ratio of Ajanta Pharma Ltd?
The Price to Earnings (P/E) Ratio of Ajanta Pharma Ltd is 35.03
What is the PB Ratio of Ajanta Pharma Ltd?
The Price to Book (P/B) Ratio of Ajanta Pharma Ltd is 8.28
What is the 52 week high of Ajanta Pharma Ltd?
The 52 week high of Ajanta Pharma Ltd is ₹3,485
What is the 52 week low of Ajanta Pharma Ltd?
The 52 week low of Ajanta Pharma Ltd is ₹1,783.50

Get started with us today and
start building your wealth journey